Huamao Mark Lin

Brigatinib Versus Crizotinib in ALK Inhibitor–Naive Advanced ALK-Positive NSCLC: Final Results of Phase 3 ALTA-1L Trial

D. Ross Camidge, Hye Ryun Kim, Myung‐Ju Ahn et al. · Journal of Thoracic Oncology · 2021 · 372 citations · Full text

Medicine, Oncology, Pharmacology +12

Brigatinib Versus Crizotinib in Advanced ALK Inhibitor–Naive ALK-Positive Non–Small Cell Lung Cancer: Second Interim Analysis of the Phase III ALTA-1L Trial

D. Ross Camidge, Hye Ryun Kim, Myung‐Ju Ahn et al. · Journal of Clinical Oncology · 2020 · 367 citations · Full text

Medicine, Oncology, Pharmacology +16

Treatment Outcomes and Safety of Mobocertinib in Platinum-Pretreated Patients With <i>EGFR</i> Exon 20 Insertion–Positive Metastatic Non–Small Cell Lung Cancer

Caicun Zhou, Suresh S. Ramalingam, Tae Min Kim et al. · JAMA Oncology · 2021 · 289 citations · Full text

Medicine, Oncology, Pharmacology +15

Alisertib in Combination With Weekly Paclitaxel in Patients With Advanced Breast Cancer or Recurrent Ovarian Cancer

Gerald S. Falchook, Robert L. Coleman, A. Roszak et al. · JAMA Oncology · 2018 · 90 citations · Full text

Medicine, Oncology, Pharmacotherapy +16

The Oral Gonadotropin-releasing Hormone Receptor Antagonist Relugolix as Neoadjuvant/Adjuvant Androgen Deprivation Therapy to External Beam Radiotherapy in Patients with Localised Intermediate-risk Prostate Cancer: A Randomised, Open-label, Parallel-group Phase 2 Trial

David P. Dearnaley, Daniel R. Saltzstein, John E. Sylvester et al. · European Urology · 2020 · 74 citations · Full text

Medicine, Oncology, Radiation Oncology +17